Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 11/20 | 0.51 |
| ▸ | TP53 | P04637 | 11/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797074 | 0.94 | KDM4E (0.56) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4781192 | 0.91 | KDM4E (0.57) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4781351 | 0.91 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4775836 | 0.90 | ALDH1A1 (0.61) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4725438 | 0.85 | LMNA (0.55) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4778294 | 0.85 | KDM4E (0.53) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4781547 | 0.84 | KDM4E (0.64) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4778108 | 0.81 | LMNA (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4794039 | 0.80 | KDM4E (0.61) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4725426 | 0.79 | RUVBL1 (0.57) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221129-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | claimed |
| WO-2008003753-A1 | PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY | BIOVITRUM AB (PUBL) (SE) | 2008-01-10 | — | — | WO | claimed |
| US-20080221129-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1934178-A2 | SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008003753-A1 | PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY | BIOVITRUM AB (PUBL) (SE) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007041257-A2 | SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221129-A1 | New compounds | SCD, SCD5, FASN | KDM4E 3813/4885ALDH1A1 858/4885HPGD 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.